









Markets
/
Stocks
/
nasdaq-autl
/

Autolus Therapeutics PLC

AUTL

1.360USD

+0.090+7.09%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

361.95MMarket Cap

LossP/E TTM



Autolus Therapeutics PLC

1.360

+0.090+7.09%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

58 / 506

Overall Ranking

151 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 11 analysts

Buy

Current Rating

9.460

Target Price

+644.88%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 59.12% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.12M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 48.26.

Overvalued

The company’s latest PE is -1.56, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 287.25M shares, increasing 10.37% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 2.69M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.62.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 7.52, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

7.52

Change



Financials

5.46

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.46

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.43

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.45, which is 27.84% below the recent high of -1.86 and -121.99% above the recent low of -3.23.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 58/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.73, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Autolus Therapeutics PLC is 10.00, with a high of 13.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.73

Change

Support & Resistance

No Data

Analyst Rating

Based on 11 analysts

Buy

Current Rating

9.460

Target Price

+644.88%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Autolus Therapeutics PLC

AUTL

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 6.36, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 1.63 and the support level at 1.08, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.36

Change

0.31

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.028

Neutral

RSI(14)

33.354

Neutral

STOCH(KDJ)(9,3,3)

26.510

Buy

ATR(14)

0.093

Low Volatility

CCI(14)

-83.403

Neutral

Williams %R

69.531

Sell

TRIX(12,20)

-1.711

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

1.330

Buy

MA10

1.372

Sell

MA20

1.468

Sell

MA50

1.980

Sell

MA100

1.908

Sell

MA200

1.977

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 107.93%, representing a quarter-over-quarter increase of 3.24%. The largest institutional shareholder is PRFDX, holding a total of 2.69M shares, representing 1.01% of shares outstanding, with 8.35% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BioNTech SE

33.33M

Syncona Investment Management Limited

30.73M

Wellington Management Company, LLP

27.09M

+6.89%

Clarus Ventures, LLC

20.49M

MAK Capital One, LLC

15.41M

Deep Track Capital LP

17.85M

+25.53%

Syncona Portfolio Ltd

16.64M

Qatar Investment Authority

15.00M

PPF Group N.V.

14.78M

+1.16%

Armistice Capital LLC

11.00M

+19.57%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.05, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.82. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.